The mPRα-HiEx rate and average intensity of mPRα expression were marginally or significantly higher in HER2+ subtype cancers (i.e. HER2+ER-PR-) as compared to ER+ subtype cancers (P=0.05, P=0.02, respectively). This evidence concerns the gene ERBB2 and cancer.